Physician profile
Michael Dunkle
NPI 1306389846
$1,681.79
in general payments reported to CMS, 2019-2025
31 companies · $461 in 2025
The $461 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.52 · 2022: $269 · 2023: $132 · 2024: $794 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,287 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,287.45 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $240.10 | 2023-2024 | Omnipod |
| Astrazeneca Pharmaceuticals Lp | $183.53 | 2024-2025 | Enhertu, Imfinzi |
| Novo Nordisk INC | $141.58 | 2022 | |
| Novartis Pharmaceuticals Corporation | $122.15 | 2024-2025 | |
| Sobi, INC | $114.55 | 2024 | |
| Incyte Corporation | $113.64 | 2024-2025 | Jakafi, Zynyz, Monjuvi |
| Xeris Pharmaceuticals, INC. | $107.89 | 2022 | |
| Kite Pharma, INC. | $73.09 | 2025 | Yescarta |
| Abbvie INC. | $69.62 | 2022-2025 | |
| Exelixis INC. | $63.15 | 2024-2025 | Cabometyx |
| Pfizer INC. | $42.55 | 2021-2024 | |
| Servier Pharmaceuticals LLC | $41.79 | 2025 | |
| Daiichi Sankyo INC. | $38.58 | 2024 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $25.41 | 2025 | Fruzaqla |
| Alexion Pharmaceuticals, INC. | $23.82 | 2024 | Ultomiris |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $23.35 | 2024 | Monoferric |
| Genzyme Corporation | $21.81 | 2025 | |
| Legend Biotech USA INC. | $20.80 | 2025 | Carvykti |
| Jazz Pharmaceuticals INC. | $20.71 | 2025 | |
| Eisai INC. | $20.38 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $19.35 | 2025 | Opdualag |
| Emd Serono, INC. | $16.99 | 2024 | |
| Merck Sharp & Dohme LLC | $16.10 | 2024 | Keytruda |
| Acrotech Biopharma INC. | $16.00 | 2024 | Beleodaq |
| Pharmaessentia USA Corporation | $15.87 | 2024 | Besremi |
| Lilly USA, LLC | $15.57 | 2025 | Jaypirca, Verzenio |
| Becton, Dickinson and Company | $15.14 | 2021 | |
| Tempus Ai, INC | $15.09 | 2025 | Xt Cdx |
| Taiho Oncology, INC. | $14.90 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $14.27 | 2025 | Onivyde |
| Adc Therapeutics America, INC. | $14.01 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dunkle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.